Loading viewer...
investor_presentation
Format: PDF investor_presentation
A SIMPLER WAY TO LIFE November 2019CORPORATE PRESENTATIONOTC QB: IVOB
A SIMPLER WAY TO LIFE
November 2019CORPORATE PRESENTATIONOTC QB: IVOBThis presentation includes forward -looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements regarding our expected future financial position, results of operations,
cash flows, financing plans, business strategies, products and services, competitive positions,
growth opportunities, plans and objectives of management for future operations, as well as
statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar expressions are forward -looking
statements. All forward -looking statements involve risks, uncertainties and contingencies, many of
which are beyond our control, which may cause actual results, performance, or achievements to
differ materially from anticipated results, performance, or achievements. Factors that may cause
actual results to differ materially from those in the forward -looking statements include those set
forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such
obligation to) update or alter our forward -looking statements, whether as a result of new
information, future events or otherwise.INVO BIOSCIENCE –Developer and manufacturer of the INVOcell ™
•Patented , Innovative medical device technology
•FDA Cleared –in November 2015 through the De Novo pathway
•Worlds only in vivo Intravaginal culture (IVC) system -a disruptive new fertility
treatment alternative
●LARGE & UNDER SERVED MARKET –Global infertility market estimated at $20+
billion currently, despite only 1% to 2% of the estimated 150M infertile couples
currently treated due primarily to cost and access.
●SIGNED EXCLUSIVE U.S. LICENSING AGREEMENT WITH FERRING IN JAN 2019
●$5.0 million up front plus $3.0 million in additional milestone payments
●Required minimum annual revenue over the next seven (7) years.
●INITIAL COMMERCIALIZATION EFFORTS WITH FERRING UNDERWAY
●498% revenue growth in Q2 2019
●Available in approximately 100 clinics in more than 20 states
●Increasing media coverage
●INTERNATIONAL COMMERCIALIZATION EFFORTS BEGININGCOMPANY OVERVIEW
Preview truncated — download the full document for the complete content.
investor_presentation
26 Pages
investor_presentation
53 Pages
Spectrum Brands
Adani Energy Solutions Limited Investor Presentation January 2024
investor_presentationinvestor_presentation
55 Pages
Adani Energy Solutions Limited